BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch-and-wait” does not prevent or control the progression of disease, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place on January 8-11, 2024 in San Francisco.
OcuTerra President and Chief Executive Officer Kerrie Brady will present on Thursday, January 11, at 9:00 am PT in the Mission Bay room at the Westin St. Francis. Ms. Brady will share a company overview and updates on OcuTerra’s novel, selective integrin inhibitor eye drop, nesvategrast (OTT166). OcuTerra recently announced the final patient visit in the Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast. Topline results for the DR:EAM study are expected later this quarter. OcuTerra’s Chief Financial Officer, Bill Steinkrauss, and Chief Medical Officer, David J. Tanzer, MD, will also be in attendance at the conference.
“I am excited to share OcuTerra’s progress in the advancement of nesvategrast eye drops as a non-invasive, earlier intervention for diabetic retinopathy through our Phase 2 DR:EAM clinical trial,” said Ms. Brady. “The J.P. Morgan Healthcare conference is one of the most significant events in our industry, and we look forward to presenting our work to move beyond the current ‘watch-and-wait’ standard of care.”
Presentation details:
Time: 9:00 am PT, Thursday, January 11th, 2024
Location: 42nd J.P. Morgan Healthcare Conference - Private Track
Mission Bay Room, 32nd Floor, The Westin St. Francis, San Francisco, CA
About OcuTerra Therapeutics
OcuTerra Therapeutics, Inc. is developing innovative drugs for ophthalmic diseases for which the current standard of care does not prevent or control the [early] progression of disease. Our initial therapeutic candidate, nesvategrast (OTT166), administered as an eye drop containing a novel, potent and selective integrin-inhibitor, is in clinical development as an early, non-invasive intervention for diabetic retinopathy, a chronic, progressive disease that is one of the leading causes of vision loss globally. Our goal is to bring transformative treatments to patients and their clinicians who are currently consigned to watch and wait as disease progresses, ultimately requiring medically intensive and invasive therapy. www.ocuterratx.com
